stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) EV/FCF
As of 6 November 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a EV/FCF of 4.6×. Over the past ten years it has ranged from −1,665× (March 2022) to 54.0× (June 2021); the current reading is higher than 28% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 5.0× | (46.48%) |
| FY2024 | 9.3× | 0.13% |
| FY2023 | 9.3× | (67.58%) |
| FY2022 | 28.8× | — |
| FY2021 | −1,385× | — |
| FY2020 | −297× | — |
| FY2019 | −8.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 5.9× | 16.61% |
| Jun 2026 | 5.1× | 34.44% |
| Mar 2026 | 3.8× | (24.60%) |
| Dec 2025 | 5.0× | 18.73% |
| 23 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | −36.2× |
| MAZE Maze Therapeutics, Inc. compare | −15.4× |
| TRAX First Tracks Biotherapeutics, Inc. compare | −13.8× |
| MESO Mesoblast Limited compare | −13.1× |
| VIR Vir Biotechnology, Inc. compare | −11.3× |
| REPL Replimune Group, Inc. compare | −8.5× |
| HRMY Harmony Biosciences Holdings, Inc. | 4.6× |
| SRPT Sarepta Therapeutics, Inc. compare | 10.9× |
| FTRE Fortrea Holdings Inc. compare | 17.2× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))